China's Asieris Pharma Lands $14 Million for Genito-Urinary Tumor Treatments

05:10 EDT 27 Mar 2020 | ChinaBio Today

Asieris Pharma, located in Taizhou's China Medical City, raised $14 million in a C round to advance its genito-urinary tumor treatments. Its lead candidate, a novel treatment for non-muscular invasive bladder cancer, has completed China Phase III trials and a US Phase I trial. Unlike other treatments for the condition, usually bladder resection, APL-1202 is convenient, painless and does not cause damage to the urethra. A repurposed oral inhibitor of MetAP2, APL-1202 is a 50-year-old wide spectrum antibiotic that had been shown to have an anti-angiogenesis effect. More details....

Share this with colleagues:

Original Article: China's Asieris Pharma Lands $14 Million for Genito-Urinary Tumor Treatments


More From BioPortfolio on "China's Asieris Pharma Lands $14 Million for Genito-Urinary Tumor Treatments"

Quick Search

Relevant Topics

Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...